Lung Bacteria, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Office of Research, Metro North Hospital and Health Service, Brisbane, Queensland, Australia.
Intern Med J. 2019 Jun;49(6):722-728. doi: 10.1111/imj.14158.
The inter-jurisdictional National Mutual Acceptance (NMA) scheme for Human Research Ethics Committee (HREC) approvals of human research is designed to reduce the reported delays and costs of ethical review. Introduction of the NMA set forth an uncoupling of the ethics and governance review processes, permitting a single ethical review for multiple sites, while continuing separate governance review for each centre covering financial and operational aspects of the research project.
To compare the time required to gain ethics and governance approvals in Australia for a non-interventional investigator-led study from December 2015 to approval times for an earlier pre-NMA study utilising a similar study design and study sites and evaluate the effect that the NMA has had on total approval time for non-interventional multi-centre projects.
We recorded the time taken to obtain ethics and governance approval at 16 sites for our nationwide low-risk non-interventional study looking at the prevalence and aetiology of non-tuberculous mycobacterial infection in people with cystic fibrosis in Australia.
Applications were submitted to three hospitals and one university HREC to conduct our study at 16 hospital sites, HREC approval took from 16 to 79 days (median 28). Subsequent site-specific governance approval at 15 hospital sites took 23-225 days (median 83). The entire process of gaining ethical and governance approval to conduct the study at 16 sites took 24 months at an estimated cost of AU$56000 (US$ 42 000).
Lengthy governance approval processes negate benefits gained from centralised ethics review under the NMA.
国家互认(NMA)方案旨在减少伦理审查报告的延迟和成本,以促进不同司法管辖区之间的人体研究伦理委员会(HREC)批准。NMA 的引入将伦理和治理审查过程分开,允许对多个地点进行单一的伦理审查,同时继续对每个中心进行单独的治理审查,涵盖研究项目的财务和运营方面。
比较澳大利亚一项非干预性研究者主导的研究在 NMA 之前和之后获得伦理和治理批准所需的时间,该研究利用了类似的研究设计和研究地点,并评估 NMA 对非干预性多中心项目总批准时间的影响。
我们记录了在澳大利亚进行的一项全国性低风险非干预性研究的时间,该研究旨在调查囊性纤维化患者中非结核分枝杆菌感染的患病率和病因。该研究在 16 家医院和 1 家大学 HREC 进行,共记录了 16 个地点的伦理和治理批准时间。
该研究申请在 16 家医院的 3 家医院和 1 家大学 HREC 进行,HREC 批准时间为 16-79 天(中位数为 28 天)。随后在 15 家医院进行的特定地点治理批准时间为 23-225 天(中位数为 83 天)。在 16 个地点获得进行研究的伦理和治理批准的整个过程耗时 24 个月,估计费用为 56000 澳元(42000 美元)。
漫长的治理批准过程否定了 NMA 下集中伦理审查所带来的好处。